Presidio Pharmaceuticals
Pioneering The Next Generation of Antiviral Therapeutics
Skip to content
  • Home
  • About Us
    • Management Team
    • Board of Directors
    • Investors
    • Business Development
  • HCV
  • News
    • 2014
    • 2013
    • 2012
    • Archives
  • Presentations
  • Programs & Pipeline

Presentations

Recent presentations and scientific papers. Presentations are in Adobe Acrobat format unless otherwise noted.

Scientific Presentations

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial (Lancet, April 15, 2021)

High Rate of Sustained Virologic Response in Patients with HCV Genotype-1A Infection: A Phase 2 Trial of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin (EASL, April 2014)

Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection (AASLD, November 2013)

PPI-668, A Potent New Pan-Genotypic HCV NS5A Inhibitor: Phase 1 Efficacy and Safety (AASLD, November 2012)

Advertisement

Share this:

  • Twitter
  • Facebook

Like this:

Like Loading...
  • Contact Us

    Presidio Pharmaceuticals, Inc.
    1700 Owens Street, Suite 184
    San Francisco, CA 94158 USA (map)

    Phone: 415-655-7560

    Email



Presidio Pharmaceuticals
Blog at WordPress.com.
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy
    • Presidio Pharmaceuticals
    • Customize
    • Sign up
    • Log in
    • Copy shortlink
    • Report this content
    • Manage subscriptions
%d bloggers like this: